What release profile would you like to see in an extended-release midodrine?
Founded by fathers of POTS patients, Dyscovri Therapeutics is a stealth-mode company developing an oral, extended-release midodrine.

To help inform the development of our formulation, we're surveying stakeholders to understand the extended-release profile that would be most useful to treat POTS.

Thank you so much for your help!
Sign in to Google to save your progress. Learn more
Are you a POTS patient, or a physician who treats POTS? *
After how long should our extended-release formulation begin to release midodrine? *
Over how many hours should the midodrine be released?   *
How would you like the midodrine to be released?   *
Based on your knowledge of midodrine, if patients tell us they want a formulation that works "for X hours," does that mean the release profile has to end at exactly X hours or some time before or after? *
Do you have any suggestions for us? Please feel free to write as much as you want and be sure to include your contact information if you would like us to respond. Thank you!  
Submit
Clear form
Never submit passwords through Google Forms.
This form was created inside of orang-utan productions.

Does this form look suspicious? Report

Google Forms